Historical Valuation
Puma Biotechnology Inc (PBYI) is now in the Fair zone, suggesting that its current forward PS ratio of 1.26 is considered Fairly compared with the five-year average of -74.23. The fair price of Puma Biotechnology Inc (PBYI) is between 3.63 to 6.42 according to relative valuation methord.
Relative Value
Fair Zone
3.63-6.42
Current Price：6.11
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Puma Biotechnology Inc (PBYI) has a current Price-to-Book (P/B) ratio of 2.52. Compared to its 3-year average P/B ratio of 3.73 , the current P/B ratio is approximately -32.40% higher. Relative to its 5-year average P/B ratio of -0.82, the current P/B ratio is about -407.17% higher. Puma Biotechnology Inc (PBYI) has a Forward Free Cash Flow (FCF) yield of approximately 14.74%. Compared to its 3-year average FCF yield of 14.67%, the current FCF yield is approximately 0.49% lower. Relative to its 5-year average FCF yield of 7.38% , the current FCF yield is about 99.76% lower.
P/B
Median3y
3.73
Median5y
-0.82
FCF Yield
Median3y
14.67
Median5y
7.38
Competitors Valuation Multiple
AI Analysis for PBYI
The average P/S ratio for PBYI competitors is 1.49, providing a benchmark for relative valuation. Puma Biotechnology Inc Corp (PBYI.O) exhibits a P/S ratio of 1.26, which is -15.12% above the industry average. Given its robust revenue growth of -32.36%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PBYI
1Y
3Y
5Y
Market capitalization of PBYI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PBYI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PBYI currently overvalued or undervalued?
Puma Biotechnology Inc (PBYI) is now in the Fair zone, suggesting that its current forward PS ratio of 1.26 is considered Fairly compared with the five-year average of -74.23. The fair price of Puma Biotechnology Inc (PBYI) is between 3.63 to 6.42 according to relative valuation methord.
What is Puma Biotechnology Inc (PBYI) fair value?
PBYI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Puma Biotechnology Inc (PBYI) is between 3.63 to 6.42 according to relative valuation methord.
How does PBYI's valuation metrics compare to the industry average?
The average P/S ratio for PBYI's competitors is 1.49, providing a benchmark for relative valuation. Puma Biotechnology Inc Corp (PBYI) exhibits a P/S ratio of 1.26, which is -15.12% above the industry average. Given its robust revenue growth of -32.36%, this premium appears unsustainable.
What is the current P/B ratio for Puma Biotechnology Inc (PBYI) as of Jan 10 2026?
As of Jan 10 2026, Puma Biotechnology Inc (PBYI) has a P/B ratio of 2.52. This indicates that the market values PBYI at 2.52 times its book value.
What is the current FCF Yield for Puma Biotechnology Inc (PBYI) as of Jan 10 2026?
As of Jan 10 2026, Puma Biotechnology Inc (PBYI) has a FCF Yield of 14.74%. This means that for every dollar of Puma Biotechnology Inc’s market capitalization, the company generates 14.74 cents in free cash flow.
What is the current Forward P/E ratio for Puma Biotechnology Inc (PBYI) as of Jan 10 2026?
As of Jan 10 2026, Puma Biotechnology Inc (PBYI) has a Forward P/E ratio of 12.17. This means the market is willing to pay $12.17 for every dollar of Puma Biotechnology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Puma Biotechnology Inc (PBYI) as of Jan 10 2026?
As of Jan 10 2026, Puma Biotechnology Inc (PBYI) has a Forward P/S ratio of 1.26. This means the market is valuing PBYI at $1.26 for every dollar of expected revenue over the next 12 months.